DRGT_Logo_[RGB][1].jpg
DRGT Announces First Subject Dosed in a Phase I Clinical Trial of DRGT 45, a Novel Formulation of Abiraterone Acetate for Prostate Cancer
October 29, 2019 09:00 ET | Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announces the first subject dosed in a two-part Phase I trial to evaluate the pharmacokinetics,...
DRGT_Logo_[RGB][1].jpg
Druggability Technologies Holdings, Ltd (DRGT) Announces Appointment of a New Chief Executive Officer and a New President of DRGT Research
October 21, 2019 09:00 ET | Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings, Ltd (DRGT), Ltd a clinical stage specialty pharmaceutical company, announced the appointment of Lynne Powell...
DRGT_Logo_[RGB][1].jpg
DRGT Announces the U.S. FDA IND Application Approval and First Dosing of a Clinical Trial to Evaluate the Bioavailability and Food Effect of Immediate-Release Formulation of Tadalafil (DRGT-99)
September 18, 2019 09:00 ET | Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New...
DRGT_Logo_[RGB][1].jpg
DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure
July 15, 2019 09:00 ET | Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, July 15, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced the start of a phase 2 randomized, double-blind, placebo-controlled trial to evaluate...
DRGT_Logo_[RGB][1].jpg
DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor
June 10, 2019 09:00 ET | Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, June 10, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced results from a pharmacokinetic study of their novel formulation of celecoxib...
DRGT_Logo_[RGB][1].jpg
DRGT USA Announces Appointment of Dr. Elizabeth Manning Duus, as Executive Director of Clinical Development
February 05, 2019 03:22 ET | Druggability Technologies Holdings Ltd
NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies USA today announced the expansion of the clinical team, with the addition of Dr. Elizabeth Manning Duus, who has been named...
DRGT_Logo_[RGB][1].jpg
Druggability Technologies USA Announces Appointment of John E. Friend II, M.D. as Chief Medical Officer
December 06, 2018 03:29 ET | Druggability Technologies Holdings Ltd
NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Druggability Technologies USA today announced that Dr.  John E. Friend II has been named as Chief Medical Officer. Druggability Technologies USA has been...
DRGT_Logo_[RGB][1].jpg
Best in Class Erectile Dysfunction Drug - DRGT announces dose escalation study results of its Super-Tadalafil DRGT-99
May 02, 2018 05:29 ET | Druggability Technologies Holdings Ltd
MALTA, May 02, 2018 (GLOBE NEWSWIRE) -- DRGT, a specialty pharmaceutical company with a proprietary formulation technology, announced the results of its successful dose escalation PK study for...
DRGT announces results of Phase I study expanding clinical utility of the drug Sirolimus utilizing the company’s novel Super-API technology platform
October 05, 2017 05:28 ET | Druggability Technologies Holdings Ltd
MSIDA, Malta, Oct. 05, 2017 (GLOBE NEWSWIRE) -- DRGT, a specialty pharmaceutical company, today announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®),...
DRGT's novel Celecoxib composition - opportunity for low dose, immediate onset of pain relief with the only NSAID COX-2 inhibitor on the market
December 19, 2016 07:48 ET | Druggability Technologies
SWATAR, MALTA--(Marketwired - Dec. 19, 2016) - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-46 and DRGT-47 programs, new compositions...